BioSpace News Archive

With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.

Bactiguard has received a new order from Well Lead Medical in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.

Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD, the Chief Medical Officer for Mateon, Vuong Trieu, PhD, the Chief Executive Officer and President for Mateon and four hematology/oncology professors from academic US institutions in the prestigious oncology journal Cancers (Basel)

Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has successfully shipped the first cannabinoid to its partner, LAVVAN.

Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a proof of concept study of multiple myeloma with lenalidomide using a model which emulates transdermal delivery.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3 head-to-head study that compared DAYVIGO™ (lemborexant) to placebo and an active comparator in patients with insomnia disorde

CEL-SCI Corporation (NYSE American: CVM) announced the closing of an underwritten public offering of 606,395 shares of its common stock at a price of $9.07 per share, for total gross proceeds of approximately $5.5 million, before deducting underwriting discounts and other offering expenses payable by the Company.

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to people living with Lambert-Eaton Myasthenic Syndrome (LEMS).

BeiGene, Ltd. announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration as a treatment for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies.